Improving the lives of patients through less invasive medical devices.

Mission

Stealth Therapeutics is committed to improving the lives of patients, including the millions of individuals who require long-term intravenous treatment for cancer and infection. We will accomplish this by developing less invasive and less conspicuous medical devices that are more convenient, more effective, and healthier than those currently available.

History

Stealth Therapeutics was founded in January 2006 for the purpose of designing and developing a portfolio of improved venous access devices (VADs).

The company's mission and strategic approach are guided by founder Dr. Bradley Glenn, MD, a practicing Interventional Radiologist. Dr. Glenn believes it is not only possible, but necessary, to develop VADs that deliver maximum function and minimum form—that is, the best devices with the smallest possible impact on the lives of patients.

Peter Drumm, CEO

Peter Drumm, CPA, is the Chief Executive Officer of Stealth Therapeutics.

Before becoming the company's first Chief Executive Officer, Mr. Drumm was General Manager at JT Packard and Associates, a back-up power service and supply company. During his tenure with JT Packard, Mr. Drumm was instrumental in growing annual revenue from $3.5 million to $36 million, thereby transforming it into the largest independent service provider for network-critical power equipment in the United States. Mr. Drumm was also instrumental in JT Packard's successful sale in 2006.

In addition to his role as CEO, Mr. Drumm is also an investor in Stealth Therapeutics.

Bradley Glenn, Founder and CTO

Bradley Glenn, M.D., is the founder and Chief Technology Officer of Stealth Therapeutics.

Dr. Glenn is a practicing, board-certified Interventional Radiologist. Before founding Stealth Therapeutics and inventing the Invisiport, the company's first product, Dr. Glenn successfully licensed patents for three previous medical inventions to Johnson & Johnson.

In addition to his role as CTO, Dr. Glenn is also an investor in Stealth Therapeutics and a member of its Board of Directors.

Bradley Glenn

Bradley Glenn, M.D., is a practicing, board-certified Interventional Radiologist. Dr. Glenn has successfully licensed patents for three previous medical inventions to Johnson & Johnson.

Dr. Glenn is also the founder and Chief Technology Officer of Stealth Therapeutics as well as the inventor of the Invisiport.

Jake Orville

Jake Orville is the Chief Executive Officer of Prognostix, Inc., a privately-held spin out of the Cleveland Clinic Foundation that develops and markets next-generation cardiovascular disease diagnostic products.

Before joining Prognostix, Mr. Orville was the Vice President of Global Sales and Marketing at NextGen Sciences, the Vice President of Global Sales and Business Development at Third Wave Technologies, and National Sales Manager at Smiths Medical.

George Trutza

George Trutza is the Chief Executive Officer and President of Impliant, Inc., a developer of novel spine arthroplasty alternatives to fusion surgery.

Before joining Impliant, Mr. Trutza was Executive in Residence at the Cleveland Clinic's Innovation Center, a special commercialization arm of the Cleveland Clinic whose mission is to facilitate the broad and rapid deployment of Cleveland Clinic technology. Mr. Trutza has also served as President of Kendall Medical & Surgical Division and President of Tyco Healthcare Group Canada.